Skip to main content
HR 1492 119th Congress House Health Health care costs and insurance Medicare Prescription drugs

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Introduced: April 29, 2025 Introduced by: Murphy, Gregory F. Republican · North Carolina See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 21, 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 21, 2025
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. 

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation.

The bill's changes apply retroactively.

What's happening now February 21, 2025

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Lobbying activity 278

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • GSK (FKA GLAXOSMITHKLINE INC.)
    for GSK (FKA GLAXOSMITHKLINE INC.) · District of Columbia · 2nd Quarter (Apr 1 - June 30) 2026
  • LUNDBECK LLC
    for LUNDBECK LLC · District of Columbia · 2nd Quarter (Apr 1 - June 30) 2026
  • HEALTHCARE INSTITUTE OF NEW JERSEY
    for HEALTHCARE INSTITUTE OF NEW JERSEY · New Jersey · 2nd Quarter (Apr 1 - June 30) 2026
  • E3 STRATEGIC CONSULTING GROUP
    for PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Virginia · 2nd Quarter (Apr 1 - June 30) 2026
  • MARSHALL & POPP, LLC
    for SANOFI U.S. SERVICES, INC. · District of Columbia · 2nd Quarter (Apr 1 - June 30) 2026
  • MARSHALL & POPP, LLC
    for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · District of Columbia · 2nd Quarter (Apr 1 - June 30) 2026
See all 278 filings →
 Cosponsors 68
D
Moskowitz, Jared
Florida · Jun 23, 2026
D
Boyle, Brendan F.
Pennsylvania · Apr 27, 2026
D
Peters, Scott H.
California · Feb 12, 2026
R
Smith, Adrian
Nebraska · Dec 16, 2025
R
McGuire, John J.
Virginia · Oct 8, 2025
R
Huizenga, Bill
Michigan · Oct 3, 2025
R
Carter, Earl L. "Buddy"
Georgia · Sep 10, 2025
R
Fong, Vince
California · Sep 10, 2025
R
Kennedy, Mike
Utah · Jul 29, 2025
R
Miller, Max L.
Ohio · Jul 29, 2025
R
Ciscomani, Juan
Arizona · Jul 10, 2025
R
Bentz, Cliff
Oregon · Jun 26, 2025
R
Fischbach, Michelle
Minnesota · Jun 10, 2025
R
Fitzgerald, Scott
Wisconsin · Jun 6, 2025
R
Hinson, Ashley
Iowa · Jun 6, 2025
R
Kustoff, David
Tennessee · May 29, 2025
R
Nunn, Zachary
Iowa · May 19, 2025
R
Baumgartner, Michael
Washington · May 9, 2025
R
Goldman, Craig A.
Texas · May 9, 2025
R
Hern, Kevin
Oklahoma · May 9, 2025
R
Fry, Russell
South Carolina · May 8, 2025
R
Carey, Mike
Ohio · May 7, 2025
R
Fedorchak, Julie
North Dakota · May 7, 2025
R
Harshbarger, Diana
Tennessee · May 7, 2025
R
Rouzer, David
North Carolina · May 7, 2025
R
Shreve, Jefferson
Indiana · May 7, 2025
R
Harrigan, Pat
North Carolina · May 1, 2025
R
Balderson, Troy
Ohio · Apr 30, 2025
R
Cammack, Kat
Florida · Apr 29, 2025
R
Flood, Mike
Nebraska · Apr 29, 2025
R
Latta, Robert E.
Ohio · Apr 29, 2025
R
Amodei, Mark E.
Nevada · Apr 24, 2025
R
Houchin, Erin
Indiana · Apr 24, 2025
R
Ogles, Andrew
Tennessee · Apr 24, 2025
R
Rulli, Michael A.
Ohio · Apr 24, 2025
R
Smucker, Lloyd
Pennsylvania · Apr 24, 2025
R
Weber, Randy K. Sr.
Texas · Apr 24, 2025
R
Bean, Aaron
Florida · Apr 17, 2025
R
Bresnahan, Robert P.
Pennsylvania · Apr 17, 2025
R
Hill, J. French
Arkansas · Apr 17, 2025
R
Jack, Brian
Georgia · Apr 17, 2025
R
Kelly, Mike
Pennsylvania · Apr 17, 2025
R
Knott, Brad
North Carolina · Apr 17, 2025
R
McCormick, Richard
Georgia · Apr 17, 2025
R
Allen, Rick W.
Georgia · Apr 8, 2025
R
Evans, Gabe
Colorado · Apr 8, 2025
R
Haridopolos, Mike
Florida · Apr 8, 2025
R
Steil, Bryan
Wisconsin · Apr 8, 2025
R
Steube, W. Gregory
Florida · Apr 8, 2025
R
Comer, James
Kentucky · Apr 1, 2025
Page 1 of 2 Next
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1492/
MLA
"H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1492/.
Bluebook (legal)
H.R. 1492, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1492/.
Markdown link
[H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.](https://openamerica.io/bill/119-HR-1492/)
Report a problem